Colony Group LLC raised its holdings in Icon Plc (NASDAQ:ICLR) by 1.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 17,066 shares of the medical research company’s stock after acquiring an additional 325 shares during the quarter. Colony Group LLC’s holdings in Icon were worth $2,939,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. WCM Investment Management LLC raised its stake in shares of Icon by 1.3% during the fourth quarter. WCM Investment Management LLC now owns 3,643,211 shares of the medical research company’s stock valued at $627,470,000 after acquiring an additional 48,181 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Icon by 1.6% during the fourth quarter. Renaissance Technologies LLC now owns 2,347,059 shares of the medical research company’s stock valued at $404,234,000 after acquiring an additional 36,099 shares during the last quarter. Comgest Global Investors S.A.S. raised its stake in shares of Icon by 15.5% during the fourth quarter. Comgest Global Investors S.A.S. now owns 1,760,847 shares of the medical research company’s stock valued at $303,270,000 after acquiring an additional 235,944 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Icon by 14.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,590,967 shares of the medical research company’s stock valued at $274,011,000 after acquiring an additional 199,267 shares during the last quarter. Finally, American Capital Management Inc. raised its stake in shares of Icon by 0.3% during the fourth quarter. American Capital Management Inc. now owns 798,975 shares of the medical research company’s stock valued at $137,607,000 after acquiring an additional 2,501 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

ICLR has been the subject of several analyst reports. UBS Group raised their price target on shares of Icon from $174.00 to $182.00 and gave the company a “neutral” rating in a research note on Friday, February 21st. Wells Fargo & Co initiated coverage on shares of Icon in a research note on Tuesday, January 7th. They set an “equal weight” rating and a $180.00 price target for the company. BidaskClub downgraded shares of Icon from a “buy” rating to a “hold” rating in a research note on Wednesday, March 18th. Mizuho reaffirmed a “buy” rating and set a $194.00 price target (up previously from $179.00) on shares of Icon in a research note on Thursday, February 20th. Finally, Jefferies Financial Group dropped their price target on shares of Icon from $180.00 to $146.00 and set a “buy” rating for the company in a research note on Monday. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Icon presently has an average rating of “Hold” and a consensus target price of $170.27.

Shares of ICLR stock opened at $127.84 on Thursday. The company has a market cap of $6.70 billion, a P/E ratio of 18.80, a PEG ratio of 1.44 and a beta of 0.69. The stock has a 50 day simple moving average of $156.43 and a two-hundred day simple moving average of $157.74. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.44 and a current ratio of 1.44. Icon Plc has a fifty-two week low of $104.28 and a fifty-two week high of $178.99.

Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $1.83 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.83. The firm had revenue of $725.40 million for the quarter, compared to analysts’ expectations of $734.13 million. Icon had a return on equity of 24.34% and a net margin of 13.33%. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.62 EPS. On average, research analysts predict that Icon Plc will post 7.57 earnings per share for the current year.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Further Reading: How is a management fee different from a performance fee?

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.